| Project/Area Number |
22791056
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
KATO Toyoaki 東京大学, 医学部附属病院
MORIMURA Soshi 東京大学, 医学部附属病院
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ケモカイン / CCL17 / CCR4 / 創傷治癒 / 腫瘍免疫 / 表皮 / 線維芽細胞 / 制御性T細胞 / 皮下注射 / 静脈注射 / nerve growth factor / 肥満細胞 |
|---|
| Research Abstract |
The effects of CCL17 produced by epidermal keratinocytes on immunity, inflammation and regeneration in the skin were investigated. CCL17 accelerates wound healing by promotion of fibroblast migration and recruitment of CCR4+NGF-producing lymphocytes and mastcytes. CCL17 may suppress tumor immunity in the skin. Cetirizine, an antihistamine drug, has inhibitory effects on CCL17 production by epidermal keratinocytes and dermal fibroblasts. These suggest that CCL17 is a candidate drug for skin wound and inhibitors of CCL17 and its receptor, CCR4, may be available for prevention of remodeling after cutaneous inflammation and treatment for skin tumors.
|
